By HospiMedica International staff writers
Posted on 08 Sep 2020

Researchers from the University of Oxford (Oxford, UK) have found that natural infection with COVID-19 produces a robust T cell response, including inducing T cell ‘memory’ to potentially fight future infections.

While research has shown that COVID-19 induces a B cell antibody response, it has been less clear whether COVID-19 causes the immune system to make virus-specific T cells too, and whether they are important for recovery from the initial infection, and protection against new infections. While antibodies latch onto and destroy disease-causing agents like viruses and bacteria, T cells latch on to diseased cells within the body, such as tumor cells or virus-infected cells. T-cells also help attract other immune cells to the area. T cells are attracted to tumor or viral protein fragments (called epitopes) displayed on the surface of diseased cells, which act like waving a flag to the T cells, showing them where they are needed.

In their study, the Oxford researchers analyzed blood samples from COVID-19 patients to identify peptides containing T cell epitopes, including six immunodominant regions (epitope clusters) that were targeted by T cells in many of the patients. The research team compared blood samples from 28 mild and 14 severely ill COVID-19 patients, as well as samples from 16 healthy donors. The researchers found that individuals with mild COVID-19 had a different pattern of T cell response as compared to those with more severe infection, potentially providing insights into the nature of immune protection.

While the research team thinks that a poor quality T cell response might contribute to SARS-CoV-2 viral persistence and COVID-19 mortality, recovered patients with mild as well as severe disease still had T cell memory two months after infection. Only a small number of T cells need to have a memory of the primary infection, and they can replicate to mount a robust immune response quickly. The researchers also found that the spike protein of SARS-CoV-2 was often recognized by T-cells from recovered patients, which adds support for the approaches used by many of the current vaccines in development, including the Oxford vaccine. The research team additionally found that other parts of the virus, including its membrane and its nucleoprotein, also provoked a strong T cell immune response, potentially providing other vaccine targets too. The team now plan to investigate how long T cell immune memory lasts and whether this might have implications for novel diagnostic tests and new treatments.

“By studying the T cell immune response in depth and breadth, we will begin to build a better understanding of why some individuals develop milder disease, and how we might be able to prevent or treat infections,” said study lead Professor Tao Dong from the MRC Human Immunology Unit. “T cells may also be longer lasting than antibodies, and so could offer alternative methods to diagnose whether someone has had a past COVID-19 infection, after antibody levels have waned.”

Professor Dong, who is also the Founding Director of the Chinese Academy of Medical Sciences Oxford Institute (COI) based at the Nuffield Department of Medicine, University of Oxford, added “By identifying regions of the virus that are targeted by the immune system, we anticipate the findings will help define the role of T cells in disease outcomes."

Related Links:
University of Oxford